medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2004, Number 5

<< Back Next >>

Rev Mex Oftalmol 2004; 78 (5)

Correlación entre grosor macular y capacidad visual en pacientes con retinopatía diabética y edema macular clínicamente significativo

Alvarez CMD, Fromow-Guerra J, Guerrero-Naranjo JL, Quiroz-Mercado H

Language: Spanish
References: 29
Page: 230-236
PDF size: 299.08 Kb.


ABSTRACT

Purpose: To determine if there is correlation between best corrected visual acuity and macular thickness in eyes with proliferative diabetic retinopathy and concomitant clinically significant macular edema, before and after macular and scatter laser treatment. In addition, to determine if intravitreal triamcinolone modifies that correlation.
Methods: Best corrected visual acuity and macular thickness (using optic coherence tomography) were measured in both eyes of patients with diabetic retinopathy and concomitant macular edema before and after macular and scatter laser treatment. In one eye of each patient intravitreal triamcinolone was injected before the laser treatment. Best corrected visual acuity and macular thickness were measured 3 months latter.
Results: No correlation was found between the variables before or after the laser treatment.
Conclusions: There is no correlation between macular thickness and best corrected visual acuity. The degree of the retinopathy and the time in which the macular edema has been present could be implicated in this lack of correlation. Intravitreal triamcinolone did not modify the correlation. It would be important to study other parameters of macular and retinal function to assess other effects of the intravitreal steroids and laser treatment in eyes with proliferative diabetic retinopathy and concomitant clinically significant macular edema.


REFERENCES

  1. Mensaje de la Sociedad Mexicana de Oftalmología 2002 en materia de prevención de la retinopatía diabética. Oftalmología Mexicana 2002, 9(9).

  2. Aiello LP, Gardner TW, King GW, Blanknenship G, Cavallerano JD, Ferris FL, Klein R. Diabetic Retinopathy. Diabetes Care 1998, 21:143-156.

  3. Ginsburg L, Aiello L. Diabetic Retinopathy: classification, progression and management. Focal Points. Clinical Modules for Ophthalmologists 1993, 11(7).

  4. Klein R, Klein BEK, Moss SE y col. The Wisconsin Epidemiologyc Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 1984, 91:1464-1474.

  5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985, 103:1796-1806.

  6. McDonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophtahlmology 1985, 92:388-393.

  7. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002, 109:920-927.

  8. Aiello LP, Avery R, Arrigg P, Keyt BA, Jampel D, Shah ST y col. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Eng J Med 1994, 331:1480-1487.

  9. Antonetti DA, Barber AJ, Khin S Lieth E, Tarbell JM, Gardner TW, Penn State Retina Research Group. Vascular permeability in experimental diabetes associated with reduced endothelial occludine content. Diabetes 1998, 47:1953-1959.

  10. Lewis H. The role of vitrectomy in the treatment of diabetic macular edema. Am J Ophthalmol 2001, 1:123-125.

  11. Tano Y, Chandler D, Machemer R. Treatment of intraocualr proliferation with intravitreal inyection of triamcinolone acetonide. Am J Ophthalmol 1980, 90:810-816.

  12. Jonas JB, Hayler JK, Panda JS. Intravitreal injection of cristalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000, 84:1064-1067.

  13. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental preretinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993, 231:34-40.

  14. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996, 103:2099-2104.

  15. Challa JK, Gillies MC, Penfold PL y col. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZJ Ophthalmol 1998, 26:277-281.

  16. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in age related macular degeneration. Retina 2000, 20:244-250.

  17. Benitez del Castillo JM, García Sanchez J. Inyección intravitrea de tiamcinolona acetónido en uveítis no infecciosas. Arch Soc Esp Oftalmol 2001, 76:661-664.

  18. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopaty. Arch Opthalmol 2002, 119:1380-1383.

  19. Wilson CA, Berkowits BA, Sato Y, Ando N, Handa HT, de Juan E. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992, 110:1155-1159.

  20. Lovestam A, Agarth E. Corticosteroids inhibit the expression of the vascular endoterlial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998, 341(2-3):309-315.

  21. Massin P, Vicaut E, Haouchine B, Erginay A, Paques M, Gaudric A. Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol 2001, 119:1135-1142.

  22. Hee MR, Puliafito CA, Carlton W, Ducker JS, Reichel E, Rutledge B y col. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 1995, 113:1019-1029.

  23. Sánchez-Tocino H, Álvarez-Vidal A, Maldonado MJ, Moreno- Montañés J, García-Layana A. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002, 43:1588-1594.

  24. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Ophthalmol 1999, 127:688-693.

  25. Hee MR, Puliafito CA, Duker JS, Reichel E, Coker JG, Wilkins JR y col. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998, 105:360-370.

  26. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Ophthalmol 1999, 127:688-693.

  27. Talwar D, Sharma N, Pai A, Azad RV, Kohli A, Virdi PS. Contrast sensitivity following focal laser photocoagulation in clinically significant macular edema due to diabetic retinopathy. Clin Exp Ophtahlmol 2001, 29(1):17-21.

  28. Greenstein VC, Holopigian K, Hood DC, Seiple W, Carr RE. The nature and extent of retinal disfunction associated with diabetic macular edema. Invest Ophthalmol Vis Sci. 2000, 41:3643-3654.

  29. Greenstein VC, Chen H, Hood DC, Holopigian K, Seiple W, Carr RE. Retinal function in diabetic macular edema after focal laser photocoagulation. Invest Ophthalmol Vis Sci. 2000, 41:3655-3664.




2020     |     www.medigraphic.com